PriceTargets.com logo

Nu Skin Enterprises - NUS Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $8.88
  • Forecasted Upside: 18.49%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.49 As of 11/20/2024 01:00 AM ET
▼ -0.1 (-1.32%)

This chart shows the closing price for NUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Nu Skin Enterprises Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NUS

Analyst Price Target is $8.88
▲ +18.49% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Nu Skin Enterprises in the last 3 months. The average price target is $8.88, with a high forecast of $11.00 and a low forecast of $6.75. The average price target represents a 18.49% upside from the last price of $7.49.

This chart shows the closing price for NUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 2 polled investment analysts is to hold stock in Nu Skin Enterprises. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
8/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
11/26/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
2/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
5/24/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
10/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/22/2024CitigroupLower TargetNeutral ➝ Neutral$11.50 ➝ $6.75
8/12/2024DA DavidsonLower TargetNeutral ➝ Neutral$12.50 ➝ $11.00
8/9/2024CitigroupLower TargetNeutral ➝ Neutral$14.00 ➝ $11.50
5/9/2024DA DavidsonLower TargetNeutral ➝ Neutral$15.50 ➝ $12.50
1/5/2024DA DavidsonLower TargetNeutral ➝ Neutral$29.00 ➝ $21.00
10/16/2023Stifel NicolausLower TargetHold ➝ Hold$35.00 ➝ $27.00
9/29/2023CitigroupLower TargetNeutral ➝ Neutral$30.00 ➝ $23.00
8/3/2023DA DavidsonLower TargetNeutral ➝ Neutral$38.00 ➝ $29.00
8/2/2023Stifel NicolausLower TargetHold ➝ Hold$43.00 ➝ $35.00
3/1/2023CitigroupBoost TargetNeutral$35.00 ➝ $41.00
2/16/2023DA DavidsonLower TargetNeutral$40.00 ➝ $38.00
1/30/2023Jefferies Financial GroupDowngradeBuy ➝ Hold$43.00 ➝ $39.00
12/20/2022DA DavidsonBoost Target$34.00 ➝ $40.00
11/23/2022DA DavidsonLower TargetNeutral$40.00 ➝ $34.00
11/4/2022CitigroupLower Target$39.00 ➝ $35.00
10/5/2022CitigroupLower TargetNeutral$47.00 ➝ $39.00
8/23/2022DA DavidsonLower TargetNeutral$45.00 ➝ $40.00
8/8/2022CitigroupBoost TargetNeutral$45.00 ➝ $47.00
2/17/2022Jefferies Financial GroupBoost Target$61.00 ➝ $75.00
2/17/2022DA DavidsonBoost TargetNeutral$47.00 ➝ $50.00
11/24/2021CitigroupBoost TargetNeutral$43.00 ➝ $49.00
10/12/2021CitigroupLower TargetNeutral$59.00 ➝ $43.00
10/6/2021DA DavidsonLower TargetNeutral$61.00 ➝ $47.00
10/1/2021Tigress FinancialReiterated RatingBuy$72.00
5/6/2021Deutsche Bank AktiengesellschaftBoost TargetHold$57.00 ➝ $64.00
2/12/2021DA DavidsonDowngradeBuy ➝ Neutral$71.00 ➝ $58.00
2/2/2021Jefferies Financial GroupBoost TargetBuy$60.00 ➝ $66.00
11/5/2020Deutsche Bank AktiengesellschaftBoost TargetHold$49.00 ➝ $57.00
10/2/2020DA DavidsonBoost TargetPositive ➝ Buy$61.00 ➝ $68.00
10/2/2020Bank of AmericaUpgradeUnderperform ➝ Neutral$54.00 ➝ $58.00
9/30/2020Jefferies Financial GroupBoost TargetBuy$57.00 ➝ $60.00
8/6/2020Stifel NicolausBoost TargetHold$50.00 ➝ $55.00
8/6/2020Jefferies Financial GroupBoost TargetBuy$50.00 ➝ $57.00
8/6/2020DA DavidsonBoost TargetBuy$54.00 ➝ $61.00
8/6/2020Deutsche Bank AktiengesellschaftBoost TargetHold$35.00 ➝ $49.00
7/7/2020CitigroupReiterated RatingHold$41.00
7/2/2020DA DavidsonUpgradeNeutral ➝ Buy$35.00 ➝ $54.00
7/2/2020Jefferies Financial GroupUpgradeHold ➝ Buy$42.00 ➝ $50.00
6/24/2020CitigroupBoost TargetNeutral$29.00 ➝ $41.00
6/11/2020Stifel NicolausBoost TargetHold$35.00 ➝ $36.00
5/29/2020Tigress FinancialReiterated RatingBuy
5/7/2020CitigroupBoost TargetNeutral$25.00 ➝ $29.00
5/7/2020Deutsche Bank AktiengesellschaftBoost TargetHold$28.00 ➝ $35.00
3/9/2020Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$40.00 ➝ $28.00
2/14/2020CitigroupLower TargetNeutral$43.00 ➝ $33.00
2/13/2020Bank of AmericaLower TargetUnderperform$40.00 ➝ $30.00
2/13/2020DA DavidsonReiterated RatingIn-Line$35.00
12/5/2019CitigroupReiterated RatingNeutral$43.00
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.23 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2024
  • 7 very positive mentions
  • 14 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2024
  • 5 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2024
  • 4 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/21/2024
  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/20/2024

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Nu Skin Enterprises logo
Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa and ageLOC LumiSpa iO; and nutricentials skin care products. The company also provides wellness products, such as LifePak nutritional supplements, ageLOC TR90 weight management system, and Beauty Focus Collagen+. In addition, it is involved in the research and product development of skin care products and nutritional supplements. The company sells its products under the Nu Skin, Pharmanex, and ageLOC brands through retail stores, website, digital platforms, and independent direct sellers and marketers, as well as a service center. Nu Skin Enterprises, Inc. was founded in 1984 and is headquartered in Provo, Utah.
Read More

Today's Range

Now: $7.49
Low: $7.34
High: $7.71

50 Day Range

MA: $6.76
Low: $6.07
High: $7.81

52 Week Range

Now: $7.49
Low: $5.95
High: $20.75

Volume

810,722 shs

Average Volume

832,076 shs

Market Capitalization

$372.33 million

P/E Ratio

N/A

Dividend Yield

3.16%

Beta

1.14

Frequently Asked Questions

What sell-side analysts currently cover shares of Nu Skin Enterprises?

The following Wall Street analysts have issued stock ratings on Nu Skin Enterprises in the last twelve months: Citigroup Inc., DA Davidson, and StockNews.com.
View the latest analyst ratings for NUS.

What is the current price target for Nu Skin Enterprises?

0 Wall Street analysts have set twelve-month price targets for Nu Skin Enterprises in the last year. Their average twelve-month price target is $8.88, suggesting a possible upside of 18.5%. DA Davidson has the highest price target set, predicting NUS will reach $11.00 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $6.75 for Nu Skin Enterprises in the next year.
View the latest price targets for NUS.

What is the current consensus analyst rating for Nu Skin Enterprises?

Nu Skin Enterprises currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NUS, but not buy more shares or sell existing shares.
View the latest ratings for NUS.

What other companies compete with Nu Skin Enterprises?

Other companies that are similar to Nu Skin Enterprises include Herbalife, USANA Health Sciences, Nature's Sunshine Products, Medifast and Veru. Learn More about companies similar to Nu Skin Enterprises.

How do I contact Nu Skin Enterprises' investor relations team?

Nu Skin Enterprises' physical mailing address is 75 WEST CENTER ST, PROVO UT, 84601. The company's listed phone number is (801) 345-1000 and its investor relations email address is [email protected]. The official website for Nu Skin Enterprises is www.nuskinenterprises.com. Learn More about contacing Nu Skin Enterprises investor relations.